The role of bevacizumab in the treatment of non-small cell lung cancer: Current indications and future developments

Oncologist

Volumn 12, Issue 10, 2007, Pages 1183-1193

  Gridelli, Cesare ^a   Maione, Paolo ^a   Rossi, Antonio ^a   De Marinis, Filippo ^b  

^a S G MOSCATI HOSPITAL   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Angiogenesis; Bevacizumab; NSCLC; Targeted therapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADJUVANT THERAPY; ANGIOGENESIS; BLEEDING; BLOOD TOXICITY; BRAIN HEMORRHAGE; BREAST CANCER; CANCER CHEMOTHERAPY; CARCINOGENESIS; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIVERTICULITIS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG SAFETY; EMBOLISM; EPISTAXIS; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPONATREMIA; INTESTINE ISCHEMIA; LIVER FAILURE; LUNG CANCER; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NEUTROPENIA; PERITONEAL PERFORATION; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; REVIEW; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; VEIN THROMBOSIS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 36148992949     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-10-1183     Document Type: Review

References (51)

1. Jemal A, Siegel R, Ward E et al. Cancer Statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Parkin DM, Bray F, Ferlay J et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-156.
3. Bria E, Cuppone F, Cecere FL et al. Adjuvant chemotherapy for non-small cell lung cancer. J Thorac Oncol 2007;2(5 suppl):S7-S11.
4. Rigas JR, Kelly K. Current treatment paradigms for locally advanced non-small cell lung cancer. J Thorac Oncol 2007;2(suppl 2):S77-S85.
5. Scagliotti G. Optimizing chemotherapy for patients with advanced non-small cell lung cancer. J Thorac Oncol 2007;2(suppl 2):S86-S91.
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005;353:123-132.
7. Gridelli C, Rossi A, Maione P. New antiangiogenetic agents and non-small cell lung cancer. Crit Rev Oncol Hematol 2006;60:76-86.
8. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
9. Manegold C, von Pawel J, Zatloukal P et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 2007;25(18 suppl):LBA7514.
10. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
11. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-1186.
12. Folkman J. Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. Cancer Metastasis Rev 1990;9:171-174.
13. Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: Prognostic and therapeutic implications. J Clin Oncol 2005;23:3243-3256.
14. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-1027.
15. Meert AP, Paesmans M, Martin B et al. The role of microvessel density on the survival of patients with lung cancer: A systematic review of the literature with meta-analysis. Br J Cancer 2002;87:694-701.
16. Fontanini G, Lucchi M, Vignati S et al. Angiogenesis as a prognostic indicator of survival in non-small-cell carcinoma: A prospective study. J Natl Cancer Inst 1997;89:881-886.
17. Ushijima C, Tsukamoto S, Yamazaki K et al. High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression. Lung Cancer 2001;34:233-241.
18. Trivella M, Pezzella F, Pastorino U et al. Microvessel density as a prognostic factor in non-small-cell lung carcinoma: A meta-analysis of individual patient data. Lancet Oncol 2007;8:488-499.
19. Keshet E, Ben-Sasson SA. Anticancer drug targets: Approaching angiogenesis. J Clin Invest 1999;104:1497-1501.
20. Zebrowski BK, Yano S, Liu W et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 1999;5:3364-3368.
21. Zebrowski BK, Liu W, Ramirez K et al. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 1999;6:373-378.
22. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
23. Houck K, Ferrara N, Winer J et al. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991;5:1806-1814.
24. Ferrera N. Vascular endothelial growth factor. Trends Cardiovasc Med 1993;3:244-250.
25. Kaipainen A, Korhonen J, Mustonen T et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A 1995;92:3566-3570.
26. Paavonen K, Puolakkainen P, Jussila L et al. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol 2000;156:1499-1504.
27. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
28. Miller KD, Sledge GW, Burstein HJ. Angiogenesis inhibition in the treatment of breast cancer: A review of studies presented at the 2006 San Antonio Breast Cancer Symposium. Clin Adv Hematol Oncol 2007;5:1-12.
29. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
30. William WN, Kies MS, Fossella SV et al. Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25(18 suppl):691S.
31. Dalsania CJ, Hageboutros A, Harris E et al. Phase II trial of bevacizumab plus pemetrexed and carboplatin in previously untreated advanced nonsquamous non-small cell lung cancer. J Clin Oncol 2007;25(18 suppl):697S.
32. Patel JD, Hensing TA, Villafor V. Pemetrexed and carboplatin plus bevacizumab for advanced non-squamous non-small cell lung cancer (NSCLC): Preliminary results. J Clin Oncol 2007;25(18 suppl):409S.
33. Davila E, Lilenbaum R, Raez L et al. Phase II trial of oxaliplatin and gemcitabine with bevacizumab in first-line advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006;24(18 suppl):673S.
34. Waples JM, Auerbach M, Boccia R et al. A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer. J Clin Oncol 2007;25(18 suppl):685S.
35. Reynolds C, Barrera D, Vu DQ. An open-label, phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in first-line patients with advanced non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25(18 suppl):611S.
36. Heist RS, Fidias P, Huberman M. Phase II trial of oxaliplatin, pemetrexed, and bevacizumab in previously-treated advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25(18 suppl):634S.
37. Havlik RJ, Yancik R, Long S et al. The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer 1994;74(7 suppl):2101-2106.
38. Merza T, Howard LM, Junagadhwalla M. Exclusions to use of bevacizumab in elderly veterans with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25(18 suppl):687S.
39. Gridelli C, Perrone F, Gallo C et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-372.
40. Ramalingam SS, Dahlberg SE, Langer CJ et al. Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study. J Clin Oncol 2007;25(18 suppl):393S.
41. Maione P, Gridelli C, Troiani T et al. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. The Oncologist 2006;11:274-284.
42. Hirata A, Ogawa S, Kometani T et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002;62:2554-2560.
43. Ciardiello F, Caputo R, Damiano V et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003;9:1546-1556.
44. Ciardiello F, Bianco R, Damiano V et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000;6:3739-3747.
45. Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:2544-2555.
46. Tsao AS, Herbst R, Sandler A et al. Phase I/II trial of bevacizumab plus erlotinib for patients with recurrent non-small cell lung cancer: Correlation of treatment response with mutations of the EGFR tyrosine kinase gene. J Clin Oncol 2005;23(16 suppl):643s.
47. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
48. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
49. Fehrenbacher L, O'Neill V, Belani C et al. A phase II, multicenter, randomized clinical trial to evacuate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. J Clin Oncol 2006;24(suppl 18S):379S.
50. Groen HJ, Smit EF, Dingemans A. A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25(18 suppl):415S.
51. Rizvi NA, Rusch V, Zhao B. Single agent bevacizumab and bevacizumab in combination with docetaxel and cisplatin as induction therapy for resectable IB-IIIA non-small cell lung cancer. J Clin Oncol 2007;25 (18 suppl):687S.